Brii Biosciences Limited (HK:2137) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Brii Biosciences Limited has announced promising results from its Phase 2 ENSURE study, showcasing the potential of elebsiran in combination with pegylated interferon alpha to achieve higher hepatitis B virus (HBV) seroclearance rates. The study revealed that elebsiran significantly outperformed the interferon therapy alone, indicating its potential as a key component in developing a functional cure for chronic HBV. This development could attract investor interest as the company continues to advance clinical trials and explores new combination therapies.
For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.
